Trials
3 active
18 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Phase Ⅰb/Phase Ⅱ: SHR-1701: injection, intravenous infusion Almonertinib: tablets, oral”In the company’s words, NCT05503888 on ClinicalTrials.gov
- Tested for
- Gastric or Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Relapsed or Advanced Non-small Cell Lung Cancer
- Main trialPhase 3
- “This study is a randomized, Double-Blind, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of SHR1701 combined with chemotherapy in the treatment of Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. For Part 1 study,the tolerability of SHR-1701 will be evaluated and determine the recommended dose for Part 2.For Part 2 study, all enrolled patients will be randomized to 2 groups and continuously treated until the end criteria of treatment was met.”In the company’s words, NCT04950322 on ClinicalTrials.gov
- Other names
- Gemcitabine and Albumin Paclitaxel
Other drugs for Advanced Gastric Cancer
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up2
- 30 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 May 2024 | A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer | |
| Phase 2Recruiting | Dec 2027 | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | |
| Phase 1/2Not yet recruiting | 30 Jul 2027 | Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer | |
| Phase 3Terminated | 12 Aug 2024 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer | |
| Phase 3Unknown | 30 Dec 2024 | A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer | |
| Phase 2/3Terminated | 3 Apr 2024 | Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer | |
| Phase 2/3Terminated | 17 Apr 2024 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | |
| Phase 2Withdrawn | 15 Nov 2021 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC | |
| Phase 2Unknown | 31 Dec 2022 | A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer | |
| Phase 2Unknown | Jan 2023 | SHR-1701 in Patients With Recurrent/Metastatic Scchn | |
| Phase 2Unknown | 15 Jul 2023 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | |
| Phase 1/2Completed | 16 Sep 2021 | A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer | |
| Phase 1/2Unknown | May 2022 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | |
| Phase 1/2Unknown | 1 Dec 2022 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | |
| Phase 1Unknown | 16 Apr 2022 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | |
| Phase 1Unknown | 31 Dec 2022 | SHR-1701 in Metastatic or Locally Advanced Solid Tumors | |
| Phase 1Completed | 1 Feb 2023 | A Trial of SHR-1701 in Subjects With Advanced Solid Tumors | |
| Phase 1Unknown | Mar 2023 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026